Antipsychotic "Black Box" Warning Will Caution Against Off-Label Use In Dementia
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is requesting class labeling describing clinical trial results that show a higher rate of mortality in patients treated with atypical antipsychotics for dementia-related behavioral disorders compared to placebo. FDA's public health advisory and physician alert affect seven products.
You may also be interested in...
FDA Adds Black Box Warning To Label For Conventional Antipsychotics
Physicians advised of increased mortality risk when the drugs are used off-label to treat psychosis in elderly dementia patients.
FDA Adds Black Box Warning To Label For Conventional Antipsychotics
Physicians advised of increased mortality risk when the drugs are used off-label to treat psychosis in elderly dementia patients.
Otsuka, Justice Dept. Settle Charges For Off-Label Abilify Marketing
Japanese pharma agrees to pay $4 million to state and federal agencies.